Bristol Outperforms In Q3, But Will Dapagliflozin, Apixaban See It Past Plavix?
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma beats analysts' estimates for the third quarter, but all eyes are turned toward its pipeline as the Plavix patent expiry becomes a near-term reality.
You may also be interested in...
Despite Early Yervoy Success And Promise Of Eliquis, BMS Predicts Overall Net Sales Decline For 2012
With top-seller Plavix about to go off-patent in May, Bristol lowers expectations for 2012 sales while talking up its pipeline strength.
AstraZeneca Strengthens Diabetes R&D With Option On Astellas/Prosidion's Early-Stage Compounds
AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.
AstraZeneca Strengthens Diabetes R&D With Option On Prosidion's Early-Stage Compounds
AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.